Capability Statement
Acknowledgement of Country
In Australia, we acknowledge the Traditional Custodians of the lands where we operate, and pay our respects to Elders past and present. This report was prepared on the lands of the Yuggera and Turrbal people in South Brisbane. Across Icon Group, we acknowledge and respect the history and contributions of First Nations peoples. As a global organisation, we honour and respect Indigenous cultures around the world, and recognise and value the strength of Indigenous knowledge in helping us provide the best possible care possible.
Introduction
Icon Group (Icon) is a leading integrated cancer care provider with a global reach across Australia, New Zealand, ASEAN, Mainland China and the United Kingdom.
Icon is built on a strong but simple mission – to deliver the best care possible to as many people as possible, as close to home as possible. The group brings together all aspects of quality cancer care including medical oncology, haematology, radiation oncology, research theranostics, compounding, and pharmacy support services to deliver a truly integrated, end-to-end seamless service for cancer patients.
With more than 4,000 team members, a network of more than 350 doctors, over 55 cancer centres, six compounding facilities and operational support of 70 plus pharmacies, Icon is delivering world-leading care and helping address the global cancer burden.
Our mission
To deliver the best care possible, to as many people as possible, as close to home as possible.
Our vision
Deliver world-leading, integrated healthcare and address the global cancer burden.
Our Values
We are a values-driven organisation with a commitment to ensuring our people feel valued and make our patients, whether they are directly in front of us or at the end of the service we provide, feel equally as valued.
We have developed a high-performance organisational culture that encourages and supports our people to live our values and deliver excellence in care.
Energy Bringing a positive energy to everything we do Innovate Finding new and better ways of doing what we do
Connect Building and maintaining relationships with our patients and customers
On-Purpose
Doing everything with the aim to deliver exceptional healthcare
Nurture
Caring for patients and their families during the most challenging of times
Our Brands
Icon Group is the umbrella company encompassing services delivered by the following brands:
Icon Cancer Centre
Operates 55+ cancer centres in Australia, Singapore, Mainland China, Indonesia and the United Kingdom. Our cancer services deliver comprehensive care and research across metropolitan, outer-metropolitan, and regional communities, as well as outreach clinics in Australia and throughout Southeast Asia.
Icon Health Screening
A dedicated health screening service in Singapore delivering comprehensive screening for a range of health conditions with access to diagnostic services.
Icon Haematology
A Singapore clinic delivering diagnosis, treatment and management for a wide-range of haematological conditions including benign conditions and blood cancers.
Slade Health
A leading provider of specialised compounding pharmacy services operating in Australia and New Zealand. Slade deliver specialised compounded medications for oncology, hospital, and healthcare providers.
Slade Pharmacy
Australia’s market leader in the provision of medicine management services to the private hospital and oncology sectors. Icon Group provides a complete suite of services to support Slade Pharmacy operations and Slade proprietors.
Epic Pharmacy
An established provider of quality medicine and health management services to the Australian hospital, and oncology sectors. The business services public and private sector hospitals. Icon Group provides a complete suite of services to support Epic Pharmacy operations and Epic proprietors.
Pharmaxo
A UK-based leading pharmaceutical specialist manufacturer and clinical homecare provider. Pharmaxo encompasses:
Bath ASU – UK’s largest independent aseptic service provider specialising in oncology products.
Pharmaxo Healthcare – Out of hospital care services providing speciality pharmacy and homecare services.
Pharmaxo Scientific – Delivers software development and cutting-edge science and technology solutions for healthcare services and medicines.
Icon Cancer Foundation
A not-for-profit organisation who work with Icon Cancer Centre Australia to fund vital cancer research and clinical trials. ICF is a separate entity independent from Icon Group.
Joint Ventures
The following are joint ventures with collaborative organisations.
Bowen Icon Cancer Centre
A joint venture with New Zealand’s Evolution Healthcare delivering fully integrated private cancer care in Wellington.
Icon Oncology
A joint venture with Malaysia’s Sunsuria Healthcare. Operates cancer care services in Penang with plans to expand services in the region.
5D Clinics
Australia’s only private provider of radiosurgery treatment using the CyberKnife System. This joint venture see the two organisations open and operate CyberKnife centres across Australia’s east coast.
Sustainability
Across our services and regions, Icon has global reach and impact. As a world-leading integrated healthcare provider, we take seriously our responsibility to deliver our services sustainably across environment, social and governance (ESG).
Care for Patients
Leading quality cancer care globally, expanding cancer awareness, clinical competency and access and quality care for at risk communities.
Care for People
Supporting our communities, creating diverse, inclusive and attractive work environments for our teams to deliver the best for our patients.
Care for Planet
Actively working towards a lower waste and carbon footprint.
Visit icongroup.global/en/sustainability to learn more about our ESG program and goals.
UNITED KINGDOM
Five cancer centres and one management service agreement
Healthcare partnership
Two cancer centres
Our Global Impact
Over 55 cancer centres globally
3.5 million+ patient interactions annually
Delivers support services for 70+ pharmacies across hospital and retail
Australia’s largest private cancer clinical trials program with growing global reach
Delivers 1.3 million infusions annually across ANZ
A network of 350+ internationally recognised specialists
Sunsuria
Partnership with Bali International Hospital
SINGAPORE
Delivers support services for 70+ pharmacies
40 cancer centres
One cancer centre
AUSTRALIA
Six cancer centres including flagship Mt Alvernia integrated centre
Three centres delivering research
One health screening centre
NEW ZEALAND
Drug stability and research lab
Four TGA licensed compounding facilities
23 centres delivering research Research capabilities
One cancer centre One GMP licensed compounding facility
INDONESIA
MALAYSIA
Icon is led by a highly experienced and respected executive and clinical leadership team that is deeply committed to delivering exceptional healthcare. Their combined expertise and dedication drive Icon’s mission to address the global cancer burden through quality care, innovative solutions, and collaborative partnerships.
Our Leadership Executive Leadership
Mark Middleton OAM Group Chief Executive Officer
Katharine Armstrong
Head of Legal & Company Secretary
Conal Henderson Chief Financial Officer
Dr Ian Irving Chief Medical Officer
Ross Koscharsky Global Director – Icon Cancer Centre
Tracey Fyvie Chief of Staff and Chief Transformation Officer
Jenny Hansen Chief Marketing and Communication Officer
Serena Wee Chief Executive Officer - Icon ASEAN
Ian Muir
Chief Executive OfficerPharmaxo Group
Samantha Douglas Executive Manager – People and Capabilty
Paul Fenton
Chief Executive Officer – Icon Cancer Centre AU/NZ
Aldo Rolfo
Chief Executive Officer - Icon Europe
Trent Aland Executive Manager –Clinical Care
Mark Macdonald
Chief Information Officer
Chelsea Ren
Chief Executive Officer – Icon Cancer Centre Mainland China
Russell Hill Chief Executive Officer –Pharmacy and Compounding
Sophie Mepham PhD Executive Manager –Research
Clinical Leadership
A/Prof Matthew Foote Deputy Chief Medical Officer
A/Prof James Morton AM Director of Haematology (AU/NZ)
A/Prof Louise Nott Director of Medical Oncology (AU/NZ)
A/Prof Jonathan Ramsay
Group Director of Research (Radiation Medicine & Theranostics)
Dr Ian Irving Chief Medical Officer
Dr Marcel Knesl Director of Radiation Oncology (AU/NZ)
Dr Craig Gedye
Group Director of Research (Medical Oncology & Haematology)
Dr Karmen Wong
Chief Medical Officer (Singapore)
Dr Jason Butler
Haematology Research Committee Chair
Prof Sandro Porceddu
Radiation Medicine Research Committee Chair
Nigel Anderson
Group Director of Radiation Therapy
Dr Penny Kechagioglou Chief Medical Officer (UK)
A/Prof Jim Coward
Medical Oncology and Phase I Research Committee Chair
Dr Brian Stein
Research Director (South Australia)
Margie Hjorth
Group Director of Nursing
Dr Nat Lenzo
Clinical Director Molecular Imaging & Nuclear Oncology (Asia Pacific)
Dr Hsieh Wen-Son
Singapore Research Committee Chair
Trent Aland
Executive Manager –Clinical Care
Anthony Walsh
Group Director of Medical Physics
Board
The Icon Group Board is made up of highly experienced healthcare and business leaders providing strategic and cultural leadership.
Paul McClintock AO Chair
Jill Watts
Non-Executive Director
Mark Middleton OAM Executive Director
Jean-Luc Butel Non-Executive Director
Ken Wong Non-Executive Director
Dr Ian Irving Executive Director
Zita Peach Non-Executive Director
Prof John Zalcberg AO Non-Executive Director
Our History
Icon was formed in 2015 however the businesses that make-up the group have been pillars of the Australian and Singaporean healthcare community for decades. We came together to realise a joint mission to deliver comprehensive exceptional healthcare.
2012
• Haematology and Oncology Clinics of Australia (HOCA – est. 1988) and three Epic pharmacies (formerly APHS pharmacy) formed a partnership to establish Icon Cancer Care.
2014
• Acquisition of three radiation oncology businesses:
– Radiation Oncology Queensland (ROC – est. 2007)
– Radiation Oncology Institute (ROI – est. 1976)
– Oceania Oncology (est. 2010)
2015
• Slade Pharmacy and Epic Pharmacy contract Icon Group to deliver support services for their national pharmacy networks.
• Slade Health joins and brings McBeath and acquisition of Fresinius Kabi.
2016
• Opens Australia’s first private integrated cancer centre (first of many across the network).
• Joint venture with Acurity Health (now Evolution Healthcare) entering New Zealand.
• Acquisition of Singapore Oncology Consultants entering Asia market.
2017
• Acquires Epworth Radiation Oncology.
• Welcomes new majority investment consortium partners – Goldman Sachs, QIC, and Pagoda Investments.
• Cancer division is rebranded to Icon Cancer Centre.
2019
• Acquires SunTech Medical entering the Hong Kong market.
• Becomes first Australian healthcare company to deliver cancer care in Mainland China.
2020
• Acquisition of Ashford Cancer Centre Research (ACCR).
• Opened three more centres in Mainland China.
2021
• Slade Health expands into New Zealand.
• Icon welcomes new majority investors, EQT Private Equity.
2022
• Slade Health opens Australia’s first drug stability and research laboratory.
• Signs five-year research agreement with Varian.
2023
• Opens first integrated cancer centre in Singapore marking our radiation oncology entry.
• Announces entry into UK with Nuffield Health.
• Signs partnership with Sunsuria Healthcare to enter Malaysia market.
• Slade Health expands to New Zealand, opens compounding facility in Woodville.
2024
• Exits Hong Kong and commences services in Penang, Malaysia.
• Acquires Nuffield Health’s Cancer Centre London.
• Signs joint venture with 5D Clinics to deliver CyberKnife centres in Australia.
• Acquires Pharmaxo Group to enter UK’s compounding market.
2025
• Slade Pharmacy signs new agreement to continue pharmacy services to Epworth’s hospitals for a further 10 years.
• Partners with Bali International Hospital to deliver cancer care.
• Announces first two Gamma Knife centres in Australia.
• Announces three new Icon Cancer Centre locations at Nuffield Health hospitals in Brighton, Derby and Warwickshire.
• Commences services at Prince Court Medical Centre, Kuala Lumpur, Malaysia.
• Announces entry into Germany via a strategic partnership with Evidia.
Cancer Care
We deliver leading comprehensive integrated cancer care including radiation oncology, medical oncology, haematology, clinical research, theranostics and access to cancer screening and specialised services.
Icon operates 55+ Icon Cancer Centre locations across Australia, New Zealand, Singapore, Malaysia, and the United Kingdom.
Our cancer division network comprises over 350 doctors including medical oncologists, haematologists, radiation oncologists, nuclear medical physicians, and surgical oncologists, working alongside a multidisciplinary medical professional team of radiation therapists, medical physicists, oncology nurses, clinical research staff and administrative teams.
Together, we deliver care across metropolitan, outer-metropolitan, and regional communities, as well as outreach clinics in Australia and throughout Southeast Asia.
Partnership with Nuffield Health
One cancer centre with a strong pipeline of radiation oncology centres
Evidia partnership
Partnership with Sunsuria Health
Two cancer centres with planned growth
Six cancer centres
One Health Screening clinic
Specialist services including paediatric oncology
40+ cancer centres
Six Public Private Partnerships
Theranostics Program
First-to-market in world-class technology and treatments
Proven trackrecord of longterm Public Private Partnerships
Five cancer centres
Delivers world-class radiation oncology in partnership with local hospitals
One cancer centre in partnership with Bali International Hospital
One joint venture cancer centre
First Australian company to deliver cancer care in Mainland China
MAINLAND CHINA
NEW ZEALAND
SINGAPORE AUSTRALIA
MALAYSIA INDONESIA
Pioneers in Comprehensive Cancer Care
• First private day oncology provider in Australia and Singapore.
• First Australian healthcare company to deliver cancer care in Mainland China.
• In 2023, opened Singapore’s first comprehensive cancer centre, including all aspects of cancer care.
State-of-the-Art Technology
• Global partnership with Varian Medical Systems, a Siemens Healthineers company.
• First-to-market of the latest in radiation oncology technology e.g.
– First in Australasia to install a Varian Halcyon System
– First in Australasia to deliver Varian’s HyperArc technology
– First in southern hemisphere to deliver artificial intelligence treatment with Varian’s Ethos therapy
– First in southern hemisphere to implement Varian’s HyperSight technology and RapidArc Dynamic.
• Utilises Radformation’s AIpowered contouring and adaptive radiotherapy solutions.
Regional Insight
• Over 50% of Australia cancer centres are in outer-metro and regional communities.
• Deep experience in medical tourism and local hospital partnerships across Southeast Asia.
Icon Cancer Centre Mildura brings radiation therapy closer to home
Icon Cancer Centre Mildura is transforming cancer care in regional Victoria, delivering world-class treatment options to patients in the heart of their own community.
With a focus on bringing cutting-edge care closer to home, the centre eliminates the need for patients to travel long distances to access life-saving treatments such as radiation therapy and chemotherapy.
In its first two years, the centre has made a significant impact on patients in Sunraysia and nearby regions having completed more than 8,600 individual radiation treatment sessions and over 500 patients have completed their radiation therapy treatment.
Equipped with the latest technology, Icon Cancer Centre Mildura ensures that local residents receive the same high standard of care available in metropolitan hospitals.
“No longer do local cancer patients need to travel long distances from loved ones to access the care they need or face financial and emotional stress during what can be months of treatment,” Icon Group CEO, Mark Middleton said.
Regional cancer care isn’t just about treating cancer or installing a machine. It is always about community.”
Research and Clinical Trials
Research is in Icon’s DNA and is an integral part of the care we provide our patients. We operate Australia’s largest private cancer clinical trials program with a growing global reach.
With research a relatively uncommon practice in a private healthcare setting, Icon is extremely proud of the depth and experience within our dedicated research arm that has been operating for over 35 years. Icon conducts Phase I – IV across medical oncology, haematology and radiation oncology including trials sponsored by the pharmaceutical industry, collaborative studies with universities and industry groups, and a strong in-house investigator-initiated trials program. We are also actively involved in clinical trials within our pharmacy and compounding divisions.
Exploring research opportunities
Three centres delivering research
Paediatric oncology trials
Theranostics
One centre with research capabilities
20+ cancer centres delivering research
National leader of private Phase I clinical trials
Theranostics clinical trials
NEW ZEALAND
SINGAPORE
AUSTRALIA
UNITED KINGDOM
Compounding
Under the Slade Health brand, Icon operates Australia’s leading compounding service with 60 years’ experience in the pharmaceutical industry.
Founded on a commitment to patient care, quality, innovation and integrity, Slade Health operates a strong network of TGA and GMP licensed manufacturing facilities across the Australian eastern seaboard and New Zealand and deliver 60% of Australia’s chemotherapy compounding and 40% in New Zealand.
In 2024, Icon expanded its compounding capabilities with the acquisition of Pharmaxo Group – owner of Bath ASU, Pharamxo Healthcare and Pharmaxo Scientific, a leading specialist manufacturer and clinical homecare provider based in Corsham, Wiltshire.
One compounding facility
One GMP licensed facilirty
One government contract
Four TGA licensed facilities (QLD, NSW, VIC, SA)
State-of-the-art stability and research laboratory (out of Sydney)
Several government contracts
UNITED KINGDOM
60 years’ industry experience
Over 1.3 million infusions produced annually across ANZ
Dedication to quality
• In Australia 99.84% delivery of products in full and on time.
• In 2022 opened a Stability Testing and Research Laboratory lab first of its kind in Australia.
• Unique barcoding system with inner bags and easy tear off to reduce risk of cytotoxic spills.
Six TGA/ GMP licensed compounding facility
Several state government contracts
Seven Public Private Partnerships with Australia/New Zealand governments
Continual growth
• In 2015, Slade acquired oncology compounding business, Fresenius Kabi Australia (FKA).
• In the past three years tripled its output from 300,000 to over one million infusions annually.
• 60% chemotherapy compounding market share in Australia, 40% in New Zealand.
• Employs over 400 staff including pharmacists, technicians, customer service, procurement, administration, financial management information technology and logistics.
• Renewal of government contracts to supply chemotherapy across state public hospitals.
Innovation
• Stability Testing and Research Laboratory lab extending shelf-life of life-saving medications including high-cost monoclonal antibodies.
• Centralised compounding, batch production and reduced wastage for cost efficiencies.
• Developed SHOT (Slade Health Order Tracking) platform – a digital ordering system for hospital partners with real-time tracking.
Pharmacy
Icon provides a complete suite of services to support the operation of more than 70 Slade and Epic pharmacies across Australia.
The pharmacy proprietors of Slade and Epic contract Icon Group to deliver support services such as human resource management, IT, finance and marketing.
About Slade and Epic pharmacies
These pharmacies specialise in hospital and oncology pharmacy, as well as retail pharmacy. This includes regional and metropolitan locations in both public and private hospitals that range from 31 to 900 beds. They also support and participate in clinical trials and specialist services such as IVF and sterile and non-sterile pharmacy compounding.
Adeney
Auchenflower x 3
Bendigo
Box Hill
Brisbane Waters
Brunswick
Burnside
Camberwell
Canberra x 2
Chermside x 2
Currumbin
Deakin
East Melbourne x 3
Epping
Fitzroy
Forster
Frankston
Geelong
Hobart x 2
Hollywood
Hunter Valley
Hurstville
Kangaroo Point
Kempsey
Kew
King Meadows
Kurralta Park
Lismore
Mackay
Maitland
Merewether
Midland
Mornington
Mt Kuring-gai
Mt Lawley
Mulgrave
Murdoch x 2
Newcastle x 2
New Town
Noble Park
North Gosford
North Lakes
North Sydney
Northern Beaches
Port Macquarie x 2
Richmond
Robina
Rockingham
Ryde
South Brisbane
Southport
Spring Hill x 2
Sunshine Coast
Taree
Toowoomba x 2
Toronto
Townsville x 2
Urraween
Warragul
Werribee
Westmead
Whyalla
Windsor Gardens
Icon supports services of over 70 pharmacies
Large hospital contracts nationwide
Specialty pharmacy services
Robust national clinical governance and quality management
Specialised comprehensive care
• Offers the full remit of hospital pharmacy services with extensive oncology services.
• Management and participation in clinical trials alongside hospital partners and Icon centres.
• A wide range of specialised services including IVF, Botulinum toxin, sterile and non-sterile pharmacy compounding and veterinary products.
Procurement efficiency
• Achieves economies of scale through deep industry partnerships.
• Centralised procurement model and inventory systems to reduce waste, control costs and maintain high standards of patient care.
Commitment to quality and innovation
• A mature national Quality and Medication Safety Unit (QMSU) ensuring quality and safety across all pharmacy operations.
• Compliance with all aspects of the NSQHS Standards.
• Delivers an innovative pharmacy audit systems with standardised assessments, facilitating clinical benchmarking and reporting.
• Leading digital solutions to ensure best-practice medication safety and hospital efficiencies.
Quality and Safety
Icon prioritises excellence in quality, safety and governance across our healthcare services. Underpinned by a global governance framework structure, we provide safe and exceptional patient-centred care.
Icon’s robust approach to clinical governance ensures the care we deliver meets best practice and adheres to all relevant and required regional guidelines, audits and regulatory licensing and compliance. We promote risk and incident management through a continuous improvement cycle, reinforcing a culture of transparency and quality improvement.
Above national standards in first Australian Council on Healthcare Standards (ACHS) SNAP (Short Notice Assessment Pathway) accreditation.
Dedicated Radiation Therapy Practice Unit (RTPU) oversees global policies, procedures and governance.
Supports the operation of the Quality and Medication Safety Unit (QMSU) who support the pharmacies with clinical governance, quality and safety of all Slade and Epic pharmacies. QMSU deliver a robust Pharmacy Audit Program which standardises assessment across all hospital pharmacies, facilitating benchmarking and reporting of key performance indicators.
Icon Singapore were the first oncology centre in Asia to achieve Australian Council on Healthcare Standards International (ACHSI) accreditation.
Global training and education , including remote capabilities to ensure clinical teams maintain consistent standards and keep up-to-date with new protocols.
Innovation and Technology
The introduction and investment in remote clinical capabilities has removed geographical barriers of healthcare, allowing Icon to grow in existing regions and new markets to deliver more care to more people.
Remote radiation therapy planning
Icon proudly operates a unique remote radiation therapy planning arm. This service model sees a centralised team of specialist radiation therapists and dosimetrists use advanced software systems to create individual, high quality treatment plans for radiation therapy patients.
Remote planning is one of the most cutting-edge telehealth exports in Australian healthcare and increases planning efficiencies and quality across Icon’s global network.
This service means our patients are treated with the highest quality in a timely manner, anywhere in the world.
Global Agile Radiation Therapy Workforce
Icon’s Global Agile Radiation Therapy (ART) tool leverages Icon’s global network of cancer centres and radiation therapists to share workloads across 35+ sites across Australia and Singapore, streamlining workflows and increasing efficiencies to deliver more care to more people, closer to home.
ART addresses the healthcare workforce crisis by enabling resource-sharing across Icon’s global network, mitigating burnout and human errors that arise from siloed operations. By redistributing available time from sites with capacity to those in need, we enhance care delivery closer to home, particularly in smaller, underserved and regional areas. This approach not only reduces the volatility of workloads at individual sites, managing staff risk of burnout, but also improves patient care, efficiencies, and quality.
Remote training and education
Icon provides a robust radiation therapy training program using Assisted Reality (AR) headsets to effectively deliver clinical training and competency across the international network for radiation therapists, medical physicists and oncology nurses. Our remote training program ensures a consistent world-class standard of care.
Pharmacy digital solutions
ChartFlow electronic ordering
Used across the national Slade and Epic network, Chartflow supports real-time transmission of orders and prioritisation to assist efficiency within the pharmacy.
Reports real-time dispensary performance monitoring and visibility.
Nurse ordering and dashboard
Nurses can place orders electronically with real-time transmission to pharmacy. These orders are queued based on requested completion time and shows live order status providing seamless patient care.
Compounding digital solutions
SladeConnect – a secure digital education platform developed exclusively for pharmacy and hospital partners. SladeConnect offers full product and pricing catalogue, stability updates, comprehensive educational resources and clinical request portal and customer support.
• Slade Health’s SHOT – Slade Health Order Tracking (SHOT) is a digital platform that offers real-time order placement, tracking and review of Slade products.
• AXIS – a bespoke PIC/s compliant compounding software.
• E-QMS – a fully electronic Quality Management System.
Global partnership options
Icon Group can offer a suite of options to support and complement global healthcare services, both public and private.
Radiation Treatment and SACT
Overflow Services
Remote overnight radiation treatment planning services
Remote radiation equipment commissioning services
Operational reviews, benchmarking & performace improvement services
Public Private Services Agreements Managed Services Agreements
Industry partners
Icon invests in partnerships to deliver exceptional cancer care and build genuine, meaningful collaborations between individuals and groups dedicated to making a positive impact. Icon’s emphasis on nurturing partnerships is the hallmark of our care model. We are proud to work alongside leading national and international organisations, medical experts, researchers, industry providers and advocacy groups to ensure we can continue to effectively deliver care to more people.
City Cancer Challenge (C/Can)
Icon partners with the City Cancer Challenge Foundation (C/Can), to support their mission to improve access to quality cancer treatment in LMIC’s around the world. Icon business leaders, medical and clinical experts provide their knowledge and skills to C/Can projects focussed on designing, planning and implementation of effective cancer care solutions.
International Hospital Federation (IHF)
In early 2024 Icon Group became a Premier Associate Member of the International Hospital Federation (IHF). Established in 1929 and headquarted in Geneva, Switzerland, IHF is the only international membership body for the leaders and managers of hospital and health systems. The IHF is a global not-for-profit, non-governmental organisation. IHF bring together members to share knowledge, strengthening the work of member and provide opportunities for exchange, development and collaboration. IHF members are part of a community of over 25,000 hospitals shaping the future of healthcare around the world. In 2025 Icon extended our partnership with IHF becoming a collaborative sponsor of the Women in Leadership Special Interest Group (SIG) supporting women in leadership roles across the healthcare sector.
Omico
Icon Cancer Centre partners with Omico, a not-for-profit organisation accelerating access to precision oncology trials. The partnership aims to advance cancer care by making precision oncology more accessible in routine practice. It provides Australians living with challenging cancers access to free comprehensive genomic profiling (CGP), opening the door to life-extending, personalised treatments that may otherwise remain unexplored.
Radformation
In 2025 Icon Group signed a Centre of Excellence Agreement with Radformation, a leading provider of automation software for radiotherapy. This strategic partnership demonstrates our commitment to advancing cancer care through technology and innovation. It sees Icon collaborate on Radformation product testing, case studies and research, and early adoption of AI driven tools to achieve efficiencies and better patient outcomes.
Varian Medical Systems
Varian is the world’s leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiation.
This is complemented by Icon’s role as a member of the Varian Adaptive Intelligence Consortium, working alongside other peak international bodies to develop clinical and technical aspects of Varian’s adaptive technology and wider radiation therapy treatments.
